Navigation Links
ANA598 Demonstrates Positive 4-Week Results at 200 mg BID
Date:12/17/2009

SAN DIEGO, Dec. 17 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) today announced preliminary results from a planned interim analysis of data at four weeks for the first dose cohort, 200 mg bid, in an ongoing Phase II study of ANA598 in combination with pegylated interferon and ribavirin (SOC) in HCV patients. 56% of patients receiving ANA598 plus SOC achieved undetectable levels of virus (<15 IU/ml) at week 4, known as Rapid Virological Response or RVR, compared to 20% of patients receiving placebo plus SOC.

ANA598 was well tolerated through four weeks, with no serious adverse events reported. An independent Data Monitoring Committee (DMC) has endorsed escalating to the second dose level, 400 mg bid, and this cohort is now open for enrollment. Anadys expects to initiate dosing in this cohort in January 2010.

"We are very pleased with the 4-week antiviral response and safety for this first dose cohort," said Steve Worland, Ph.D., President and CEO. "We look forward to the upcoming 12-week data, including antiviral response known as cEVR, for the 200 mg bid cohort in the first quarter of 2010 as well as RVR and cEVR data for the 400 mg bid cohort in the second quarter of 2010. With this additional data and results of subsequent trials, we hope to see ANA598 established as the leading non-nucleoside in HCV, suitable for combination with current standard of care as well as with other direct antivirals currently in development."

"This first Phase II data clearly demonstrates the ability of ANA598 to improve antiviral response at week 4 above what is seen with current standard of care alone," said James L. Freddo, M.D., Senior Vice President, Drug Development and Chief Medical Officer. "The RVR rate combined with a good safety and tolerability profile to date is
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
6. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
7. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
8. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
11. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... DIEGO , Dec. 23, 2014 ResMed (NYSE: ... significant patent infringement action against Chinese medical device manufacturer BMC ... (ITC) ruled today that BMC,s masks listed below infringe ResMed,s ... or selling these masks in the United States ... iVolve N2 nasal mask , Willow nasal pillows mask ...
(Date:12/24/2014)... ALEXANDRIA, Va. , Dec. 23, 2014 /PRNewswire-USNewswire/ ... stringent diastolic blood pressure target for people with ... either moderate or high doses of statins, in ... risk management enacted by the American College of ... recommendations are reflected in the most recent changes ...
(Date:12/22/2014)... 2014  CytoSorbents Corporation (OTCQB:CTSOD), a critical care ... technology to help fight deadly inflammation in critically-ill ... today announced the appointment of Dr. Gregory ... Senior Vice President of Clinical Development, effective January ... Russo is an accomplished pediatric cardiothoracic surgeon ...
Breaking Medicine Technology:ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
... 22, 2011 AuraSense Therapeutics, a biopharmaceutical ... as gene regulation- and chemo-therapeutics for a ... dermatology, neurology, and for cardiovascular disorders, has ... Abbott Biotech Ventures, a subsidiary of Abbott.  ...
... The Myth that physicians workload lessens its ... the New Year quickly approaching physicians are preparing for some ... depicts Healthcare IT spending by physicians and other healthcare is ... year, with most of it attributed to electronic health record ...
Cached Medicine Technology:AuraSense Therapeutics Secures Series B Equity Investment 2Medicalbillersandcoders.com Puts its Service Offers to Physicians Who Strive to Streamline Their Practice This Holiday Season! 2Medicalbillersandcoders.com Puts its Service Offers to Physicians Who Strive to Streamline Their Practice This Holiday Season! 3Medicalbillersandcoders.com Puts its Service Offers to Physicians Who Strive to Streamline Their Practice This Holiday Season! 4
(Date:12/25/2014)... (PRWEB) December 26, 2014 Recently, iFitDress.com, the ... for women, has announced its new selection of black ... are on sale now; they are available at discounted prices, ... says, “The promotion will last for three weeks only. You ... market. Those who are interested in our new items can ...
(Date:12/25/2014)... BambooFlooringChina.com sells many bamboo products and the business ... company announces big discounts on its bamboo mats ... BambooFlooringChina.com is the world’s leader in bamboo flooring. According ... Jan. 20, 2015. , The bamboo mats are made ... thread. All the bamboo strips for the mats are ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. ... chronic illnesses can receive effective, less expensive care from a ... to a team of dedicated health care professionals, a new ... ill and need either hospitalization or a trip to the ... home clinic at the University of Texas in Houston versus ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. ... on a "fountain of youth" drug that can delay the ... a new study suggests. Seniors received a significant boost ... a genetic signaling pathway linked to aging and immune function, ... The experimental medication, a version of the drug rapamycin, improved ...
(Date:12/25/2014)... 25, 2014 Plugin creators from Pixel ... A fully customizable business presentation tool made specifically for ... ProFire 5k business tool, users can now display their ... of Pixel Film Studios. “ProFire 5k gives users a ... add professionalism to a presentation” , Pixel Film Studios ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2
... , CUPERTINO, Calif., Sept. 17 DURECT ... scheduled to present at two upcoming healthcare conferences. , , ... , Matt Hogan, Chief Financial Officer, will ... on Wednesday, September 23rd at 10:30 a.m. Eastern Time. A ...
... , , MOUNTAIN VIEW, ... first and leading providers of kidney dialysis services and a ... The Polycystic Kidney Disease Foundation,s "Pathway to a Cure" walk ... held Sunday, September 20, 2009 at The Capital Building, 1315 ...
... , , , ... Somanetics Corporation (Nasdaq: SMTS ) today reported net revenues ... percent increase from $12.4 million in the same period of 2008. For ... $35.5 million from $33.8 million. , , U.S. net revenues ...
... , , , ... of a plan to expand its brand, Nutrisystem Inc., (Nasdaq: ... market Nutrisystem J Diet in Japan. Capitalizing on the success of Nutrisystem ... North America, House Foods will begin to sell Nutrisystem J Diet in ...
... , , , ... is an important time for families and eyesight, as many schools ... With the start of a new school year, it,s also a ... the environment and establish every day green habits. With this in ...
... , , , ... management provider Avizent announced today that Adrienne Paler, Executive Vice President ... the Disability Management Employer Coalition (DMEC). , , ... to the organization. Ms. Paler worked to write and enhance ...
Cached Medicine News:Health News:DURECT Corporation to Participate in Upcoming Healthcare Conferences 2Health News:Satellite Healthcare Helps Support the Cure for Kidney Disease in Sacramento 2Health News:Somanetics Reports Financial Results for the Third Quarter of Fiscal 2009 2Health News:Somanetics Reports Financial Results for the Third Quarter of Fiscal 2009 3Health News:Somanetics Reports Financial Results for the Third Quarter of Fiscal 2009 4Health News:Somanetics Reports Financial Results for the Third Quarter of Fiscal 2009 5Health News:Somanetics Reports Financial Results for the Third Quarter of Fiscal 2009 6Health News:Somanetics Reports Financial Results for the Third Quarter of Fiscal 2009 7Health News:Somanetics Reports Financial Results for the Third Quarter of Fiscal 2009 8Health News:Somanetics Reports Financial Results for the Third Quarter of Fiscal 2009 9Health News:Nutrisystem and House Foods Announce Licensing Agreement To Market Nutrisystem J Diet in Japan 2Health News:Nutrisystem and House Foods Announce Licensing Agreement To Market Nutrisystem J Diet in Japan 3Health News:Back to School Season is Time for New Green Routines 2Health News:Back to School Season is Time for New Green Routines 3Health News:Avizent Executive Earns DMEC Partnership Award 2
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... chairs are recommended for the following ... static control, health care and office. ...
... Basic ergonomic chairs with concave seats ... • Select options like seats, backrests, ... BTC/1Q chairs are recommended for the ... room, static control, health care and ...
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
Medicine Products: